A phase 2, open-label, safety and efficacy study of Panzem nanocrystal colloidal dispersion administered orally in patients with recurrent or resistant epithelial ovarian cancer

Trial Profile

A phase 2, open-label, safety and efficacy study of Panzem nanocrystal colloidal dispersion administered orally in patients with recurrent or resistant epithelial ovarian cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Oct 2014

At a glance

  • Drugs 2-methoxyestradiol (Primary)
  • Indications Ovarian cancer
  • Focus Therapeutic Use
  • Sponsors CASI Pharmaceuticals; EntreMed
  • Most Recent Events

    • 25 Nov 2008 Status changed from active, no longer recruiting to completed, reported by ClinicalTrials.gov.
    • 13 Mar 2008 Planned patient number (18) added from Clinicaltrials.gov.
    • 13 Mar 2008 The expected completion date for this trial is now 1 Aug 2008, according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top